Ntu Ⅱ: Kev lees paub ntawm tus neeg sib tw Phospholipid Biomarkers Ntawm Kab Mob Raum Hniav nyob rau hauv cov tib neeg hyperglycemic thiab lawv lub cev tshwj xeeb tshawb nrhiav hauv Leptin Receptor-Deficient Db/db Mouse
Apr 20, 2023
Kev sib tham
Raws li keeb kwm ntawm kev mob ntshav qab zib nephropathy, theem pib tshwm sim nrog rau lub raum ua haujlwm (ib txwm GFR) thiab tsis muaj qhov tsis txaus ntseeg. Qhov no yog ua raws li lub sijhawm luv luv ntawm glomerular hyperfiltration (nce GFR), ua raws li kev rov qab mus rau qhov qub thiab qeeb qeeb mus rau qhov poob qis hauv GFR nyob rau theem qis. Peb qhov kev tshawb pom ua ntej nyob rau hauv cov tib neeg longitudinal cohort qhia tias elevated serum SM C18: 1 thiab PC aa C38:0 qib yog kwv yees ntawm CKD kev loj hlob hauv cov neeg hyperglycemic nrog rau lub raum ua haujlwm ntawm lub hauv paus. Qhov kev tshawb pom ntawm tus tsiaj no thiab cov tib neeg txoj kev tshawb fawb hla ntu yog tias cov metabolites no cuam tshuam nrog cov theem ntxiv ntawm hyperglycemia-txog CKD evolution, suav nrog (i) cov kev hloov thaum ntxov uas tshwm sim los ntawm glomerular hyperfiltration (8-lub lim tiam-laus db/db nas. ) thiab (ii) tom qab hloov pauv yam ntxwv los ntawm kev txo eGFR (KORA FF4 txoj kev kawm).
Txoj kev tshawb no hla KORA FF4 tau pom muaj kev koom tes tseem ceeb ntawm cov ntshav SM C18: 1 thiab PC aaC38:0 qib thiab txo eGFR hauv cov neeg mob uas muaj ntshav qab zib los yog T2D. Lawv lub koom haum nrog rau lub raum muaj nuj nqi yog ywj siab ntawm systolic ntshav siab, lipids, HbA1C thiab UACR, qhia tias ob tus neeg sib tw phospholipid biomarkers yog ywj pheej muaj feem cuam tshuam rau CKD. Ob leeg metabolites SM C18: 1 thiab PC aa C38:0 yog phospholipids paub tswj kev mob thiab fibrosis, thiab lawv cov kev hloov pauv hauv ntshav qab zib thiab cov kab mob metabolic tshwm sim hauv ntau lub cev. Ntxiv nrog rau hyperglycemia-txuas nrog CKD, cov kev tshawb fawb metabolomics tau pom tias plasma PC aa C38:0 muaj txiaj ntsig zoo nrog kev tuag los ntawm cov kab mob hauv cov hlab ntsha, thiab kev hloov pauv hauv SM theem kwv yees T1D, T2D, thiab myocardial infarction. Raws li cov kev tshawb pom no yog cov kev pheej hmoo lossis cov txiaj ntsig tom ntej rau hyperglycemia-txuas nrog CKD, nws yog ib qho tsim nyog yuav tsum tshawb xyuas ntxiv txog tus kab mob tshwj xeeb ntawm cov phospholipid biomarkers uas tshwm sim ua ntej siv rau kev kuaj mob. Txij li tsis yog txhua tus neeg mob ntshav qab zib tsim CKD thiab tsis yog txhua tus neeg mob CKD ua raws li cov kab mob tib yam, kev tshawb nrhiav lawv cov txheej txheem ntawm kev ua haujlwm kuj tseem ceeb rau cov neeg mob stratification zoo dua thiab nrawm cov phiaj xwm tshuaj ntsuam xyuas.
Nyem qhov no mus yuavCistanche extract
Glomerular hyperfiltration yog ib qho cim ntawm kev mob ntshav qab zib raum tsis txaus. Cov ntshav ntws cuam tshuam txog kev hloov pauv ntawm glomerular thiab tubular hloov pauv los ntawm cov neeg kho tshuab kev ntxhov siab cuam tshuam nrog glomerular hyperfiltration ua lub luag haujlwm tseem ceeb hauv kev tsim cov kab mob glomerular, thiab txo qis hyperfiltration yog lub hom phiaj kho mob tseem ceeb rau kev mob ntshav qab zib CKD. Hauv cov menyuam yaus mob ntshav qab zib mellitus (6-10 lub lis piam), nce GFR thiab nce creatinine tshem tawm tau raug tshaj tawm. Hauv peb cov 8-cov nas uas muaj hnub nyoog db/db, peb pom muaj peev xwm cuam tshuam ntawm glomerular hyperfiltration nrog txo cov ntshav plasma thiab urinary creatinine qib. Creatinine yog ib qho tshuaj lom los ntawm cov khoom ntawm phosphocreatine metabolism thiab raug tso tawm los ntawm glomerular pom thiab proximal tubular secretion nrog me ntsis reabsorption. Hauv peb cov nas db / db, ntxiv rau cov ntshav thiab cov zis, qis creatinine concentrations tau pom nyob rau hauv daim siab thiab ntsws, uas tej zaum yuav yog vim txo qis creatine biosynthesis thiab / lossis phosphocreatine zog metabolism hauv cov leeg pob txha thiab lwm yam kabmob. Cov yam ntxwv paub tias cuam tshuam rau cov ntshav creatinine qhov tseem ceeb (hnub nyoog, poj niam txiv neej, haiv neeg, cov leeg nqaij, noj cov protein, thiab noj tshuaj) tsis tshua muaj txiaj ntsig, vim tias cov xwm txheej no tau tswj hwm hauv peb cov kev tshawb fawb nas. Cov nas mob ntshav qab zib twb tau txo cov pob txha loj thaum muaj hnub nyoog 5 lub lis piam thiab ua ntej qhov pib ntawm T2D, thaum cov ntshav qis creatinine hauv cov neeg mob T2D qhia txog cov leeg nqaij thiab kwv yees T2D ntawm nws tus kheej ntawm glomerular pom. Hauv cov ntsiab lus, kev ntsuas creatinine hauv 8-lub lim tiam-laus db/db nas qhia tsis tsuas yog hloov lub raum ua haujlwm, xws li glomerular hyperfiltration tab sis kuj muaj zog phosphate metabolism.
Peb cov nas db / db tau nce siab dua ntawm lub ntsws metabolites SM C18: 1 thiab PC aa C38:0 dua WT nas. Qhov no tuaj yeem qhia txog kev ua haujlwm tsis zoo ntawm lub ntsws, vim tias pc thiab SMs yog cov khoom tseem ceeb ntawm lub ntsws ua haujlwm ntawm lub ntsws thiab lawv cov kev tswj tsis zoo cuam tshuam nrog kev ua pa tsis ua haujlwm. db / db nas yog cov kab mob ntsws pulmonary edema thiab cov tsos mob ntsig txog mob hawb pob xws li kev ua pa hauv pa. Sphingomyelin synthase 2 (SMS2) deficiency attenuates o thiab txhim kho kev rov zoo tom qab mob ntsws hauv cov nas. Pulmonary dysfunction yog ib qho kev mob tshwm sim hauv cov neeg mob CKD tab sis tsis tshua muaj kev tswj xyuas kev kho mob. Txawm hais tias muaj qee cov pov thawj ntxov thiab muaj teeb meem ntawm kev ua pa nyuaj rau cov neeg laus ua pa nyuaj siab (ARDS) muaj sia nyob hauv cov neeg mob T2D, kev tshawb fawb txog kev ua tsis taus pa hauv cov neeg mob T2D tau raug yaum.
Adipose cov ntaub so ntswg ntawm cov epididymis ntawm db/db nas pom muaj qis dua ntawm SM C18: 1 thiab PC aa C38:0 (Daim duab 3). Raws li kev pom zoo nrog peb qhov kev tshawb pom, txo qis cov ntaub so ntswg adipose ntawm qee yam SMs thiab PCs kuj tau kuaj pom hauv 30-cov nas hnub nyoog db/db [38]. Phospholipid metabolism hauv cov nqaij dawb adipose thiab macrophages tau cuam tshuam loj heev hauv cov tsiaj rog. Peb kwv yees tias cov qib adipose qis hauv SM C18: 1 thiab PC aa C38:0 tej zaum yuav yog vim muaj kev nce ntxiv ntawm SM lossis PC lipid-muaj cov proteins los ntawm kev tswj hwm ATP-binding cassette transporter ABCG1 hauv cov nas rog rog.
Hauv db / db nas, nce SM C18: 1 qib hauv lub siab tuaj yeem yog qhov tshwm sim ntawm kev nce qib ntawm cov rog rog hauv lub siab cuam tshuam nrog SMS2 kev ua haujlwm, uas txiav txim siab rau daim siab thiab ntshav plasma sm. SMS2 kev ua haujlwm txhawb nqa fatty acid uptake thiab hepatic steatosis, whereas SMS2 deficiency tiv thaiv HFD-induced hepatic steatosis (44) thiab nce insulin rhiab heev. Lub siab yog lub hauv paus rau kev sib txuas thiab rov ua haujlwm ntawm phospholipids ntawm lipoprotein hais (piv txwv li, LDL / VLDL).
Herba Cistanche
Peb tau pom tias ntau dua ntawm PC aa C38:0 hauv cov qog adrenal yuav cuam tshuam nrog txo qis polyunsaturated fatty acid biosynthesis hauv cov qog adrenal ntawm db / db nas. Cov nas no kuj nthuav tawm cov tshuaj adrenal steroid ntau ntxiv, uas tuaj yeem txhawb nqa pulmonary PC synthesis ((Daim duab 3)).
Cov kua dej lom xws li ntshav thiab zis muab kev nkag siab rau hauv cov khoom nruab nrog cev metabolic crosstalk thiab lub raum ua haujlwm, feem. Zoo ib yam li creatinine, qis qis ntawm SMC18: 1 thiab PC aa C38:0 hauv cov zis ntawm db/db nas tuaj yeem cuam tshuam cov glomerular filtration thiab tsub zuj zuj ntawm phospholipids hauv lub raum cov ntaub so ntswg, raws li qhia hauv HFD-fed db/db. nas. Kev sib sau ntawm SMs hauv glomeruli ntawm cov ntshav qab zib thiab HFD-fed nas tuaj yeem txhawb nqa CKD. Mob ntshav qab zib hauv db / db nas Nephropathy tshwm sim nyob ib ncig ntawm 8 lub lis piam ntawm hnub nyoog li albuminuria thiab nce glomerular nto thaj chaw, zoo ib yam li cov theem pib ntawm tib neeg mob ntshav qab zib nephropathy, ua raws li kev nce qib hauv thylakoid matrix thiab hypertrophy. Lub raum tswj hwm HDL cov metabolism, thiab nws qhov kev ua haujlwm tsis zoo thaum ntxov tuaj yeem cuam tshuam cov roj cholesterol rov qab thiab ua rau txo qis cov zis ntawm ob qho tib si phospholipids (Daim duab 3). Hauv kev xaus, kev soj ntsuam ntxaws ntxaws ntawm ob lub kua roj ntsha thiab rau cov ntaub so ntswg hauv tus qauv nas ntawm tus mob ntshav qab zib nephropathy tau pom qhov hloov pauv ntawm SM C18: 1 thiab PC aa C38:0 hauv daim siab, ntsws, cov ntaub so ntswg adrenal, thiab zis. . Ntawm cov no, lub ntsws zoo li nthuav tshwj xeeb vim yog kev koom tes ntawm phospholipids nrog ntau yam mob ntsws thiab raug mob. Nyob rau theem no ntawm kev paub, nws tsis meej tab sis ua tau (raws li cov ntaub ntawv) uas cov kab mob no tseem tuaj yeem pab txhawb rau kev tswj hwm ntawm SM C18: 1 thiab PC aa C38:0.
Txoj kev tshawb fawb tam sim no muaj ntau qhov kev txwv thiab qhov muaj zog. Kev txwv tsis pub muaj cov ntaub ntawv nas tiv thaiv peb los ntawm kev tshuaj xyuas cov ntaub so ntswg raum thiab ua kom pom tseeb cov ntaub ntawv metabolite los ntawm kev txheeb xyuas histological. Qhov sib txawv ntawm cov keeb kwm caj ces ntawm db / db nas uas ua rau hyperglycemia thiab ntshav qab zib nephropathy piv rau tib neeg tuaj yeem cuam tshuam cov metabolite profiles. Yog li ntawd, ntau lub koom haum ntawm SM C18: 1 thiab PC aa C38:0 nyob rau hauv cov kab mob dysregulation thiab lawv cov peev xwm ua haujlwm tseem ceeb hauv lub raum kev ua haujlwm (los ntawm kev pub mis rau hauv cov qauv ntshav qab zib nas) yuav tsum tau tshawb xyuas ntxiv. Ib qho ntawm qhov muaj zog ntawm peb txoj kev tshawb fawb yog qhov kev lees paub ntawm ob tus neeg sib tw CKD biomarkers, tsis yog nyob rau hauv kev tshawb fawb ntawm tib neeg, tab sis kuj nyob rau hauv ntau lub cev nas qauv raug kev txom nyem los ntawm hyperglycemia thiab rog. Peb txoj kev tshawb fawb nthuav tawm thawj zaug ntawm ntau theem ntawm kev sib koom ua ke ntawm CKD, tus cwj pwm los ntawm glomerular hyperfiltration nyob rau theem pib (8-cov nas hnub nyoog db/db) thiab txo eGFR nyob rau theem lig (KORA FF4 kawm), Ntxiv rau qhov muaj peev xwm ua tau ntau yam hauv nruab nrog cev ntawm ob lub phospholipid metabolites rau kev tswj hwm ntawm CKD.
Cistanche ntxiv
Cov lus xaus
Txoj kev tshawb no muab kev nkag siab txog keeb kwm ntawm peb qhov kev tshawb pom tsis ntev los no ntawm SM C18: 1 thiab PC aa C38:0 raws li kev kwv yees metabolites rau kev txhim kho CKD hauv cov tib neeg hyperglycemic. Kev soj ntsuam hla ntu tau qhia tias qhov tsis zoo ntawm ob qho tib si phospholipids nrog glomerular filtration yog ywj siab ntawm systolic ntshav siab, cholesterol, triglycerides, HbA1C, thiab UACR hauv cov tib neeg hyperglycemic. Kev soj ntsuam ntau lub cev ntawm cov qauv nas ntawm cov ntshav qab zib nephropathy thaum ntxov tau qhia txog kev ua haujlwm ntawm lub ntsws, daim siab, cov ntaub so ntswg adipose, thiab cov qog adrenal hauv lawv txoj kev tswj hwm thiab CKD kev loj hlob. Raws li ib qho piv txwv zoo kawg nkaus ntawm kev sib koom tes ntawm kev sib koom tes, qhov kev tshawb fawb tib neeg thiab tsiaj txhu tau lees paub peb qhov kev tshawb pom thawj zaug thiab muab kev nkag siab txog kev sib raug zoo nrog cov txiaj ntsig ntawm lub raum ua haujlwm thiab lwm yam kabmob. Txoj kev tshawb no pab txhawb rau tib neeg kev siv tau ntawm SM C18: 1 thiab PC aa C38:0 raws li cov biomarkers tshiab rau kev txheeb xyuas ntxov ntawm cov neeg mob ntshav qab zib (pre-) uas muaj kev pheej hmoo ntawm CKD thiab yog ib kauj ruam mus rau hauv kev pheej hmoo stratification thiab txhim kho cov phiaj xwm tshuaj ntsuam xyuas rau CKD. Cov metabolites tshiab no yog qhov tsim nyog los kwv yees qhov tob molecular phenotype ntawm CKD.
Yuav ua li cas Cistanche tuaj yeem txhim kho kab mob raum rau cov tib neeg uas muaj ntshav qab zib siab
Cistanche yog ib hom tshuaj suav tshuaj uas paub zoo uas tau siv ntau pua xyoo los txhim kho lub raum ua haujlwm thiab txo cov tsos mob ntawm cov kab mob raum. Kab mob raum yog ib qho mob uas muaj feem cuam tshuam nrog cov ntshav qab zib siab, thiab Cistanche tej zaum yuav muaj txiaj ntsig zoo hauv nws txoj kev tswj hwm.
Cistanche muaj cov tshuaj bioactive xws li phenylethanoid glycosides, echinacoside, thiabActeosideuas tau pom tias muaj kev tiv thaiv antioxidant thiab tiv thaiv kab mob. Cov khoom no tuaj yeem ua lub luag haujlwm hauv kev txhim kho lub raum ua haujlwm thiab txo cov teeb meem cuam tshuam nrog rau cov kab mob raum rau cov tib neeg uas muaj ntshav qab zib ntau.
Kev tshawb fawb tau pom tias Cistanche supplementation tuaj yeem ua rau lub raum oxidative kev nyuaj siab, uas yog ib qho tseem ceeb rau kev loj hlob thiab kev loj hlob ntawm cov kab mob raum. Nws kuj tseem tuaj yeem txo qhov tso tawm ntawm cov kab mob extracellular matrix, cov txheej txheem txuas rau cov kab mob raum ntev.
Ntxiv mus, Cistanche tuaj yeem pab tswj cov ntshav qabzib, lwm qhov kev pheej hmoo rau mob raum. Ib txoj kev tshawb fawb nrog rau cov nas mob ntshav qab zib tau pom tias Cistanche extract tswj tau ua rau txo qis hauv cov ntshav qabzib thiab txhim kho lub raum ua haujlwm.
Hauv kev xaus, Cistanche tuaj yeem txhim kho kab mob raum rau cov tib neeg uas muaj ntshav qab zib ntau dhau los ntawm nws cov muaj zog antioxidant thiab tiv thaiv kab mob. Txawm li cas los xij, nws tseem ceeb heev uas yuav tau sab laj nrog tus kws kho mob ua ntej noj tshuaj ntsuab ntxiv.
Standardized Cistanche
Cov ntaub ntawv
1. Huang, J.; Hus, C.; Covic, M.; Troll, M.; Adas, J.; Zukunft, S.; Prehn, C.; Vaj, L.; Nano, J.; Scheerer, MF; ua al. Machine Learning Approaches nthuav tawm Metabolic Kos Npe ntawm Teeb Meem Mob raum Kab Mob Hauv Cov Neeg Mob Prediabetes thiab Hom 2 Ntshav Qab Zib. Ntshav Qab Zib 2020, 69, 2756–2765.
2. Fornoni, A.; Merscher, S.; Kopp, JB Lipid biology ntawm podocyte-cov kev xav tshiab muaj lub cib fim tshiab. Nat. Rev. Nephrol. 2014, 10, 379–388.
3. Russo, SB; Ross, JS; Cowart, LA Sphingolipids hauv kev rog, ntshav qab zib hom 2, thiab kab mob metabolic. Handb. Exp. Pharmacol. Xyoo 2013, 373–401.
4. Lisowska-Myjak, B. Uremic toxins thiab lawv cov teebmeem ntawm ntau lub cev. Nephron Clin. Xyaum. 2014, 128, 303–311.
5. Sharma, K.; McCue, P.; Dunn, SR Diabetic raum kab mob hauv db/db nas. Am. J. Physiol Renal Physiol 2003, 284, F1138–F1144.
6. Kim, NH; Hais, JS; Kim, NH; Chaw, A.; Li, G.; Jang, SY; Kim, MK; Li, EY; Chung, CH; Ha, H.; ua al. Metabolic hloov hauv cov zis thiab ntshav thaum lub sij hawm kev loj hlob ntawm cov ntshav qab zib raum kab mob hauv tus qauv nas. Arch. Biochem. Biophys. Xyoo 2018, 646, 90–97.
7. Yamamoto, Y.; Maeshima, Y.; Kitayama, H.; Kitamura, S.; Takazawa, Y.; Sugiyama, H.; Yamasaki, Y.; Makino, H. Tumstatin peptide, inhibitor ntawm angiogenesis, tiv thaiv glomerular hypertrophy nyob rau theem pib ntawm ntshav qab zib nephropathy. Ntshav Qab Zib 2004, 53, 1831–1840.
8. Cingel-Risti'c, V.; Schrijvers, BF; van Vliet, AK; Rau, R.; Han, VK; Poob, SL; Flyvbjerg, A. Lub raum loj hlob nyob rau hauv ib txwm thiab cov nas mob ntshav qab zib tsis cuam tshuam los ntawm tib neeg insulin-zoo li kev loj hlob zoo li kev khi cov protein-1 kev tswj hwm. Exp. Biol. Med. (Maywood) 2005, 230, 135–143.
9. Cohen, MP; Lautenslager, GT; Shearman, CW Nce urinary hom IV collagen cim txoj kev loj hlob ntawm glomerular pathology nyob rau hauv cov ntshav qab zib d/db nas. Metabolism 2001, 50, 1435–1440.
10. Trak-Smayra, V.; Paradis, V.; Masart, J.; Nasser, S.; Jebara, V.; Fromenty, B. Pathology ntawm lub siab nyob rau hauv rog rog thiab mob ntshav qab zib ob/ob thiab db/db nas noj cov zaub mov txheem los yog high-calorie. Int. J. Exp. Pathol. 2011, 92, 413–421.
11. Hofmann, A.; Peitzsch, M.; Brunssen, C.; ib. Mittag, J.; Jannasch, UA; Frenzel, UA; Brown, N.; Weldon, SM; Eisenhofer, G.; Bornstein, SR; ua al. Cov tshuaj Steroid Hormone ntau lawm hauv db/db Mouse Model of Obesity and Type 2 Diabetes. Horm. Metab. Res. 2017, 49, 43–49.
12. Chocian, G.; Chabowski, A.; Zendzian-Piotrowska, M.; Harasim, E.; Łukaszuk, B.; Górski, J. Kev noj zaub mov muaj roj ntau induces ceramide thiab sphingomyelin tsim nyob rau hauv nas lub siab nuclei. Mol. Cell Biochem. 2010, 340, 125–131.
13. Tonneijck, L.; Muskiet, MH; Smits, MM; van Bommel, EJ; Heerspink, HJ; van Raalte, DH; Joles, JA Glomerular Hyper-fifiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J. Am. Soc. Nephrol. Xyoo 2017, 28, 1023–1039.
14. Sigruener, A.; Kleber, ME; Heimerl, S.; Liebisch, G.; Schmitz, G.; Maerz, W. Glycerophospholipid thiab sphingolipid hom thiab kev tuag: Ludwigshafen Risk thiab Cardiovascular Health (LURIC). PLoS IB 2014, 9, e85724.
15. Tofte, N.; Suvitaival, T.; Taus, K.; Mattila, IM; Theilade, S.; Winther, SA; Ahluwalia, TS; Frimodt-Moller, M.; Legido-Quigley, C.; Rossing, P. Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated with Present and Future Renal Impairment in a Discovery Cohort of 637 Cov Neeg Mob Ntshav Qab Zib Hom 1. Pem hauv ntej. Endocrinol. Peb Hlis 2019, 10, 818.
16. Razquin, C.; Toledo, E.; Clis, CB; Ruiz-Canela, M.; Dennis, C.; Corella, D.; Papandreou, C.; Ros, E.; Estruch, R.; Guasch-Ferre, M.; ua al. Plasma Lipidomic Profifiling thiab Risk ntawm Hom 2 Ntshav Qab Zib nyob rau hauv qhov kev sim PREDIMED. Diabetes Care 2018, 41, 2617–2624.
17. Floegel, A.; Kuhn, T.; Sookthai, D.; Johnson, T.; Prehn, C.; Rolle-Kampczyk, UA; Otto, W.; Weikert, C.; Illig, T.; von Bergen, M. ua al. Serum metabolites thiab kev pheej hmoo ntawm myocardial infarction thiab ischemic stroke: Lub hom phiaj metabolomic mus kom ze hauv ob pawg neeg German yav tom ntej. Eur. J. Epidemiol. 2018, 33, 55–66.
18. Chagnac, A.; Zingerman, IB; Rozen-Zvi, IB; Herman-Edelstein, M. Qhov tshwm sim ntawm Glomerular Hyperfiltration: Lub luag haujlwm ntawm lub cev muaj zog hauv Pathogenesis ntawm Kab Mob Raum Mob Hauv Ntshav Qab Zib thiab Kev rog. Xyoo 2019, 143, 38–42.
19. Gartner, K. Glomerular hyperfiltration thaum pib mob ntshav qab zib mellitus hauv ob hom kab mob ntshav qab zib nas (c57bl/6j db/db thiab c57bl/ksj db/db). Diabetologia 1978, 15, 59–63.
20. Campion, CG; Sanchez-Ferras, O.; Batchu, SN Lub Luag Haujlwm Muaj Peev Xwm ntawm Cov Ntshav Qab Zib thiab Cov Tshuaj Urinary Biomarkers hauv Kev Ntsuas thiab Kev Ntsuas ntawm Mob Ntshav Qab Zib Nephropathy. Ua tau. J. Kidney Health Dis. Xyoo 2017, 4, 2054358117705371.
21. Ostler, JE; Maury, SK; Dials, J.; Rooj, SR; Devor, ST; Ziolo, MT; Periasamy, M. Cov teebmeem ntawm insulin tsis kam ntawm cov leeg pob txha loj hlob thiab kev tawm dag zog muaj peev xwm hauv hom 2 mob ntshav qab zib nas qauv. Am. J. Physiol. Endocrinol. Metab. 2014, 306, E592–E605.
22. Kashima, S.; Ib, K.; Matsumoto, M.; Akimoto, K. Low serum creatinine yog hom 2 mob ntshav qab zib mellitus ntawm cov txiv neej thiab poj niam: Yuport Health Checkup Center cohort kawm. Diabetes Metab. 2017, 43, 460–464.
23. Harita, N.; Hayashi, T.; Sato, KK; Nakamura, Y.; Yoneda, T.; Endo, G.; Kambe, H. Lower serum creatinine is a new risk factor of type 2 diabetes: Txoj kev tshawb fawb txog kev kho mob Kansai. Diabetes Care 2009, 32, 424–426.
24. Hallman, M.; Spragg, R.; Harrell, JH; Moser, KM; Gluck, L. Cov pov thawj ntawm lub ntsws surfactant txawv txav hauv kev ua pa tsis ua haujlwm. Kev tshawb fawb ntawm bronchoalveolar lavage phospholipids, kev ua haujlwm saum npoo, phospholipase kev ua, thiab ntshav myoinositol. J. Clin. Kev nqis peev. Xyoo 1982, 70, 673–683.
25. Papinska, AM; Tso, M.; Meeks, CJ; Rodgers, KE Kev tswj hwm ntev ntev ntawm angiotensin (1-7) tiv thaiv lub plawv thiab lub ntsws tsis ua haujlwm hauv tus nas qauv ntawm hom 2 mob ntshav qab zib (db / db) los ntawm kev txo qis oxidative kev nyuaj siab, mob, thiab kho cov kab mob pathological. Pharmacol. Res. 2016, 107, 372–380.
26. Lu, FL; Johnston, RA; Flynt, L.; Theman, TA; Terry, RD; Schwartzman, IB; Li, A.; Ntug Dej, SA Cov lus teb pulmonary ntau ntxiv rau cov kab mob ozone raug mob hauv cov nas rog rog db/db. Am. J. Physiol. Lub ntsws Cell Mol. Physiol. 2006, 290, L856–L865.
27. Gowda, S.; Yaj, C.; Vadgaonkar, S.; Anjum, F.; Grinkina, N.; Cutaia, M.; Jiang, XC; Wadgaonkar, R. Sphingomyelin synthase 2 (SMS2) defificiency attenuates LPS-induced ntsws raug mob. Am. J. Physiol. Lub ntsws Cell Mol. Physiol. 2011, 300, L430–L440.
28. Mukai, H.; Ming, P.; Lindholm, IB; Heimburger, UA; Barany, P.; Stenvinkel, P. Qureshi, AR Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. Ntshav Qab Zib Res. 2018, 43, 522–535.
29. Kolahian, S.; Leis, V.; Nürnberg, B. Mob ntshav qab zib mob ntsws: Qhov tseeb lossis ntawv tseeb? Rev. Endocr. Metab. Teeb meem. Xyoo 2019, 20, 303–319.
30. Giesbertz, P.; Padberg, ib.; Rein, D.; Ecker, J.; Höflle, AS; Spanier, IB; Daniel, H. Metabolite profiling nyob rau hauv plasma thiab cov ntaub so ntswg ntawm ob / ob thiab db / db nas txheeb xyuas cov cim tshiab ntawm kev rog thiab ntshav qab zib hom 2. Diabetologia 2015, 58, 2133–2143.
31. Dahik, VD; Frisdal, E.; Le Goff, W. Rewiring of Lipid Metabolism in Adipose Tissue Macrophages in Obesity: Impact on Insulin Resistance and Type 2 Diabetes. Int. J. Mol. Sci. Xyoo 2020, 21, 5505.
32. Kobayashi, A.; Takanezawa, Y.; Hirata, T.; Shimizu, Y.; Misa, K.; Kioka, N.; Arai, H.; Ua, K.; Matsuo, M. Efflflux ntawm sphingomyelin, cholesterol, thiab phosphatidylcholine los ntawm ABCG1. J. Lipid Res. 2006, 47, 1791–1802.
33. Edgel, KA; McMillen, TS; Wei, H.; Pamir, N.; Houston, IB; Caldwell, MT; Mai, PO; Oram, JF; Tso, C.; Leboeuf, RC Obesity thiab poob phaus ua rau muaj cov ntaub so ntswg adipose ABCG1 hauv db/db nas. Biochim. Biophys. Xyoo 2012, 1821, 425–434.
34. Li, Y.; Dong, J.; Ding, T.; Kuo, MS; Cai, G.; Jiang, XC; Li, Z. Sphingomyelin synthase 2 kev ua thiab daim siab steatosis: Ib qho kev cuam tshuam ntawm ceramide-mediated peroxisome proliferator-activated receptor gamma2 suppression. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1513–1520.
35. Liu, J.; Zhang, H. Li, Z.; Hailemariam, TK; Chakraborty, M.; Jiang, K.; Qias, D.; Bui, HH; Peake, DA; Kuo, MS; ua al. Sphingomyelin synthase 2 yog ib qho kev txiav txim siab rau cov ntshav plasma thiab siab sphingomyelin qib hauv cov nas. Arterioscler. Thromb. Vasc. Biol. Xyoo 2009, 29, 850–856.
36. Mitsutake, S.; Zam, K.; Yokota, H.; Yoshida, T.; Tanaka, M.; Mitsui, M.; Ib, M.; Okab, M.; Tanaka, Y.; Yamashita, T.; ua al. Kev hloov pauv tsis zoo ntawm sphingomyelin hauv lipid microdomains tswj kev loj hlob ntawm kev rog, rog rog, thiab hom 2 mob ntshav qab zib. J. Biol. Chem. 2011, 286, 28544–28555.
37. Li, Z.; Zhang, H. Liu, J.; Liang, CP; Li, Y.; Li, Y.; Teitelman, G.; Beyer, T.; Bui, HH; Peake, DA; ua al. Txo cov plasma membrane sphingomyelin nce insulin rhiab heev. Mol. Cell Bio. 2011, 31, 4205–4218.
38. Igal, RA; Mandon, EC; de Gómez Dumm, nyob rau hauv cov metabolism tsis zoo ntawm polyunsaturated fatty acids nyob rau hauv cov qog adrenal ntawm cov nas mob ntshav qab zib. Mol. Cov kab mob endocrinol. 1991, 77, 217–227, ib.
39. Gross, ib.; Ballard, PL; Ballard, RA; Jones, CT; Wilson, CM Corticosteroid stimulation ntawm phosphatidylcholine synthesis nyob rau hauv kab lis kev cai fetal luav ntsws: Pov thawj rau de novo protein synthesis kho los ntawm glucocorticoid receptors. Endocrinology 1983, 112, 829–837.
40. Decleves, AE; Zolkipli, Z.; Satriano, J.; Vaj, L.; Nakayama, T.; Rogac, M.; Le, TP; Nortier, JL; Farquhar, MG; Naviaux, RK; ua al. Kev tswj hwm ntawm lipid tsub zuj zuj los ntawm AMP-activated kinase [kho] hauv kev noj zaub mov muaj roj ntau vim yog lub raum raug mob. Raum Int. 2014, 85, 611–623.
41. Miyamoto, S.; Hsu, CC; hwm, G.; Darshi, M.; Pob zeb diamond-Stanic, M.; Decleves, AE; Slater, L.; Pennathur, S.; Taub, J.; Dorrestein, PC; ua al. Mass Spectrometry Imaging nthuav tawm Elevated Glomerular ATP / AMP hauv Kev Mob Ntshav Qab Zib / Kev rog rog thiab txheeb xyuas Sphingomyelin ua tus neeg tuaj yeem ua tau. EBioMedicine 2016, 7, 121–134.
42. Soler, MJ; Rau, M.; Batlle, D. Cov qauv kev sim tshiab ntawm cov ntshav qab zib nephropathy hauv nas cov qauv ntawm hom 2 mob ntshav qab zib: Kev siv zog rov ua dua tib neeg nephropathy. Exp. Ntshav Qab Zib Res. Xyoo 2012, 2012, 616313.
43. Becker, KA; Riethmuller, J.; Seitz, AP; Gardner, UA; Boudreau, R. Kamler, M.; ib. Kleuser, IB; Schuchman, E.; Caldwell, CC; Edwards, MJ; ua al. Sphingolipids ua lub hom phiaj rau kev nqus pa ntawm kev kho mob cystic fibrosis. Adv. Drug Deliv. Rev. 2018, 133, 66–75.
Jialing Huang1,2,3, Marcela Cov1,2,3, Cornelia Huth2, Martina Rommel1,2, Jonathan Adam1,2, Sven Zukunft4,5, Cornelia Prehn6Li Wang1,2,7, Jana Neeb2,3, Markus F. Scheerer8,9, Susanne Neschen8,10, Gabi Kastenmüller11, Christian Gieger1,2,3, Michael Laxy12, Freimut Schliess13, Jerzy Adamski4,14,15, Karsten Suhre16, Martin Hrabe de Angelis3,8,15, Annette Peters2,3thiab Rui Wang-Sattler1,2,3.
1 Kev Tshawb Fawb Ntawm Molecular Epidemiology, Helmholtz Zentrum München, 85764 Neuherberg, Lub Tebchaws Yelemees; jialing.huang@helmholtz-muenchen.de (JH); marcela.covic@helmholtz-muenchen.de (MC); martina.troll@helmholtz-muenchen.de (MR); jonathan.adam@helmholtz-muenchen.de (JA); wlrst@126.com (LW); christian.gieger@helmholtz-muenchen.de (CG)
2 Lub Tsev Haujlwm Saib Xyuas Kabmob, Helmholtz Zentrum München, 85764 Neuherberg, Lub Tebchaws Yelemees; cod.huth@gmail.com (CH); jana.nano@helmholtz-muenchen.de (JN); peters@helmholtz-muenchen.de (AP)
3 German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany; hrabe@helmholtz-muenchen.de
4 Kev Tshawb Fawb Txog Molecular Endocrinology thiab Metabolism, Helmholtz Zentrum München, 85764 Neuherberg, Lub Tebchaws Yelemees; zukunft@vrc.uni-frankfurt.de (SZ); adamski@helmholtz-muenchen.de (JA)
5 Center for Molecular Medicine, Lub Koom Haum rau Vascular Signaling, Goethe University, 60323 Frankfurt am Main, Germany
6 Metabolomics and Proteomics Core Facility, Helmholtz Zentrum München, 85764 Neuherberg, Germany; prehn@helmholtz-muenchen.de
7 Liaocheng Cov Neeg Tsev Kho Mob—Department of Scientifific Research, Shandong University Postdoctoral Work Station, Liaocheng 252000, Suav teb
8 Lub Tsev Kawm Txuj Ci Kev Tshawb Fawb, Helmholtz Zentrum München, 85764 Neuherberg, Lub Tebchaws Yelemees; markus@scheerer-home.de (MFS); susanne.neschen@mail.com (SN)
9 Bayer AG, Medical Affairs & Pharmacovigilance, 13353 Berlin, Germany
10 Sanofifi Aventis Deutschland GmbH, Industriepark Hoechst, 65929 Frankfurt am Main, Lub teb chaws Yelemees
11 Lub Tsev Kawm Ntawv ntawm Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Lub Tebchaws Yelemees; g.kastenmueller@helmholtz-muenchen.de
12 Lub Tsev Haujlwm Saib Xyuas Kev Noj Qab Haus Huv thiab Kev Tswj Xyuas Kev Noj Qab Haus Huv, Helmholtz Zentrum München, 85764 Neuherberg, Lub Tebchaws Yelemees; michael.laxy@helmholtz-muenchen.de
13 Profifil, 41460 Neuss, Lub teb chaws Yelemees; Freimut.Schliess@profifil.com
14 Department of Biochemistry, Yong Loo Lin Tsev Kawm Ntawv Tshuaj, National University of Singapore, Singapore 117597, Singapore
15 Lub rooj zaum ntawm Kev Tshawb Fawb Kev Tshawb Fawb, Lub Chaw ntawm Lub Neej thiab Khoom Noj Khoom Noj Weihenstephan, Technische Universität München, 85353 Freising, Lub Tebchaws Yelemees
16 Department of Physiology and Biophysics, Weill Cornell Medical College in Qatar (WCMC-Q), Education City, Qatar Foundation, Doha PO Box 24144, Qatar; karsten@suhre.fr
